Introduction
In 1998, only 10 years ago, one of the most successful drugs in the history of the pharmaceutical industry came to market. 1 It quickly became both a national and international blockbuster. Within a few years after its introduction to the marketplace, its name, Viagra, became the second most widely known consumer brand worldwide just slightly behind the perennial front runner, CocaCola. 2 The main reason Viagra or sildenafil, its generic name, was so successful as a drug was simply because it was both very effective as an oral erectogenic agent and its side affect profile was, relatively speaking, very benign. It only took a relatively short time period of 5 to 6 years for the product to go from the clinical testing stage to its release into the marketplace in 1998.
The product was supposedly ensconced on the shelf of Pfizer in Sandwich, England, until 1992 when it was reported in the medical literature that nitric oxide (NO) was identified as the chemical mediator in the penis that induced an erection in man. 3 What actually caught the attention of the Pfizer scientists was the fact that phosphodiesterase inhibition actually enhanced the neurogenically induced vasorelaxation response of the corporal tissue since in an earlier unpublished Pfizer clinical study on angina, sildenafil appeared to possess some erectogenic side effects of an as yet unknown mechanism. Therefore, it was postulated that if their oral drug, sildenafil, possessed similar biochemical properties to the phosphodiesterase inhibitors used in the 1992 publication and did indeed enhance corporal smooth muscle relaxation, the compound could be a successful pro-erectogenic agent because it was becoming generally accepted at that time in the late 1980's that the major cause of erectile dysfunction in most men, regardless of age, was defective corporal smooth muscle relaxation or venous leakage which we now refer to as corporal veno-occlusive dysfunction.
It is safe to state that once it was recognized in the laboratory that NO was the chemical mediator that was responsible for inducing the erectile response in the penis, the race was on to determine (1) its cell of origin in the penis; (2) whether impotence was due to a defect in the synthesis, release and/or action of NO or one of its downstream products and (3) whether phosphodiesterase inhibitors could be developed as oral agents because the only well known PDE inhibitor at that time was papaverine and its use as an oral agent was not efficacious. The answer to this latter issue turned out to be the story of Viagra, which is simply an oral form of papaverine that specifically targets the PDE5 isoenzyme in the corporal smooth muscle. Therefore, on this 10th year anniversary of the release of Viagra into the marketplace, it seems appropriate to re-visit the story of how NO as the chemical mediator of penile erection was actually discovered in the laboratory since the actual events surrounding this discovery still continues to engender some controversy and confusion. This story was presented in part as an oral presentation at a scientific symposium to honor Patrick C Walsh's 30 years of contributions in Urology at The Johns Hopkins Hospital on 30 October 2004.
Monkey see, monkey do
This entire field of modern erectile physiology can be traced back to events that transpired after Tom Lue, MD, began his fellowship in 1982 under Emil Tanagho MD, in the Department of Urology at the University of California, San Francisco. One year later in 1983, Dr Lue presented his prize winning work at the Western Section, American Urological Association meeting in Vancouver, BC on the neuroanatomy of penile erection, an extension of the same work he presented earlier that year in Las Vegas, NV, at the national American Urological Association (AUA) meeting. 4 As an aside, this meeting in Las Vegas, NV, has additional historical significance in the field of impotence since it was the locale where Dr Giles S Brindley injected himself with papaverine intracorporeally, and over the course of his lecture demonstrated to his audience visible evidence that such an injection could induce an erection This brazen display singlehandedly convinced urologists that intracorporeal injections could be an efficacious form of treatment for men with erectile dysfunction and actually is credited with launching the use of injectables as pro-erectogenic agents.
It was as a runner up to Dr Tom Lue in that contest in Vancouver, BC, in 1982 that I had the pleasure of listening to him discuss how he and his colleagues deciphered in the monkey how an erection occurred neurogenically. My interest was piqued at that time, but because of other investigative commitments, it was not until 1986 when the proverbial light bulb went on in my head. Again, it was Dr Lue who flipped that switch in my brain when he presented his seminal work on the 'mechanism of venous occlusion during erection' at the Western Section of the AUA for which he was awarded another first place prize, one of dozens he has won during his illustrious career as one of the main pioneers of erectile physiology and which was published in January of 1987. 5 As soon as I heard and saw Dr Lue's demonstration that relaxation of the corporal smooth muscle induced venous occlusion, I realized at that instant what needed to be done scientifically to elucidate the biochemical events that caused the erectile response. Our quest began the next day in our laboratory at the Harbor-UCLA Medical Center in Torrance, CA, USA.
Brainstorming
Our laboratory group of two people which consisted of Suresh C Sikka, PhD, and I, decided that our first goal was to develop a corporal smooth muscle culture to help determine what type of smooth muscle was contained within the corporal tissue. Dr Sikka who at that time was the director of our research laboratory within the Division of Urology at the Harbor-UCLA Medical Center took this task upon himself and decided to use the laboratory rat as his animal model. As luck would have it, within a few days after this meeting, a 22 year old man presented to our emergency room with a self amputation of the penis and I took him to the operating room to reattach his organ. As we began to debride the corporal tissue of the amputated organ from this 'potent' man, I decided to collect some of the discarded tissue into a culture medium. I then contacted Stan Korenman, MD, from the Division of Endocrinology at UCLA who arranged for his laboratory director, Frederick Krall, PhD, to evaluate this tissue for us. Dr Krall was a recognized expert in smooth muscle cell culture and smooth muscle physiology and within 1 to 2 days, Dr Krall began his investigations.
Our second goal was a clinical one. My ongoing hypothesis after I had heard Dr Tom Lue's 1986 lecture was whether defective corporal smooth muscle function was the reason most men had impotence. Therefore, if this were the case, it would suggest that enhancing corporal smooth muscle relaxation in these men may improve their erectile function. For this clinical investigation, I was fortunate to enlist the help of one of our UCLA urology residents, Dr Anna Rosciezewski, who was beginning her laboratory year and volunteered to work on this project. She quickly recruited 44 men with erectile dysfunction and got them to agree to have a whole litany of tests performed including but not limited to duplex scanning, dynamic infusion cavernosometry and cavernosography and penile angiography. I say that I was fortunate to enlist Dr Rosciezewski because I truly believe that it was her outgoing personality, natural charm, innate selfconfidence and her belief in the merits of the study that allowed her to recruit so many men onto the study in so little time.
The results of Drs Sikka, Rosiciezewski and Krall all came in around the same time in l987. Dr Sikka was successful in developing an ongoing rat smooth muscle cell culture while Dr Rosiciezewski demonstrated that most men regardless of their age have Discovery of NO in the penis J Rajfer 'venous leakage' or what we know is actually smooth muscle cell dysfunction or corporal venoocclusive dysfunction as the cause of their impotence. 6 But it was Dr Krall who provided us with the most significant insight into what caused the smooth muscle cells to relax. He simply showed that the human corporal smooth muscle cells responded (by its release of Ca þ 2) better to cGMP than cAMP ( Figure 1) 7 and told me those magic words, 'the cells seem to function exactly the same as the vascular smooth muscle cells that we have in the media of our peripheral arteries.' It was he who actually told me that at that time it was believed that a substance from the endothelium of the artery, termed endothelium-derived relaxing factor (EDRF), was the putative agent that caused the smooth muscle cells of the arterial media to relax, although the actual chemical or its structure was still unknown.
In an attempt to prove to myself that it was this EDRF that was the biochemical agent that caused the corporal smooth muscle cells to relax, I enlisted the help of a visiting Northwestern University medical student, Andrew Freedman, who subsequently did his residency in Urology at UCLA and is now a practicing pediatric urologist in Los Angeles. I proposed that he and Dr Sikka do the following laboratory experiment to evaluate the importance of the endothelium in corporal smooth muscle relaxation. I asked them to harvest the aorta of a number of laboratory rats and then denude the endothelium of half of the organs. With the intact and denuded aortas hanging on a column, he was to drip normal human serum through the lumen of the aorta and the effluent was to be collected by a Petri dish that was coated inside with one of Dr Sikka's rat corporal smooth muscle cell cultures. The outcome measurement for this experiment was simply Ca þ 2 efflux from the corporal smooth muscle cells. (Figure 2 ) As a positive control, we dripped papaverine through the same aortic lumen since it was known at this time that papaverine caused smooth muscle cell relaxation by releasing intracellular calcium. The results of this simple experiment convinced us that EDRF was the culprit (Table 1) . 8 
Serendipity
The last piece of the puzzle occurred one day in 1988 while I decided to hitch a ride in an elevator at UCLA that was used solely for hauling anything but people. As the door began to close, I saw a sign on the opposite wall, which indicated that this laboratory was involved in smooth muscle cell physiology. The events of the next few minutes are partially chronicled in Larry Katzenstein's book, Viagra. 9 Essentially, I ran out of the elevator and entered the partially open laboratory door and met a technician by the name of Russell Byrns who was hunched over an experiment at that time. I introduced myself and asked him some questions about what they did in their lab and whether they had heard about a compound called EDRF. He gave me a puzzled look and said the director of their lab, Louis J Ignarro, PhD, a pharmacologist, was one of the people who just recently reported that EDRF was actually a chemical called nitric oxide (NO). 10 I immediately made an appointment to see Dr Ignarro and after I told him why I was convinced that EDRF or its new moniker, NO as Dr Ignarro had recently Figure 2 Experiment that ultimately proved that an endothelial factor was responsible for corporal smooth muscle cell relaxation. rCSMC, rat corporal smooth muscle cells; þ E, endothelium of aorta intact; ÀE, endothelium of aorta denuded. 
Discovery of NO in the penis J Rajfer reported, was the chemical that induced an erectile response, we quickly made plans to prove this hypothesis. We first decided to study the rabbit corpora in vitro and if these experiments supported our hypothesis, we would then study human corporal tissue. Before we had any data, our stated goal and friendly agreement if all this came to fruition, was to publish the rabbit data in Nature and the human data in the New England Journal of Medicine (NEJM) since Dr Ignarro had not had any previous NEJM publication and I had no previous Nature publication. By late 1989, Georgette Buga, PhD, in Dr Ignarro's lab was directed to fast track this work and in a short time we determined that NO was indeed the chemical that appeared to cause neurogenically induced smooth muscle relaxation in the rabbit corpora. We submitted these data to Nature in early 1990. Nature refused to review the article because, as their editors stated, the journal had very recently published an article on NO involving the gastrointestinal tract where NO was hypothesized to be the neurotransmitter of the NANC neurons in the colon. 11 Disheartened, we then re-submitted the paper to Biochemical and Biophysical Research Communications (BBRC) in June of 1990 and BBRC published it 1 month later in July of 1990. 12 This article turned out to be the first publication that implicated NO as the chemical mediator of corporal smooth muscle relaxation (Figure 3) . The experiment showed that a neurogenic (electrically induced) stimulation of the harvested rabbit corporal tissue caused corporal smooth muscle relaxation in a dose-dependent manner and this was inhibited by compounds that blocked the synthesis and/or action of NO. Although this work was performed in the rabbit, we knew in our hearts that this was also going to turn out to be the putative chemical mediator of penile erection in man.
As an aside, when we received the rejection from Nature, Dr Ignarro decided to send a letter to the editors of Nature casting some doubt on whether NO could be the actual neurotransmitter of the NANC neurons as the Bult article 11 had suggested and stated that these data did not rule out the prospect that NO could also be emanating from the underlying smooth muscle. This correspondence to Nature included one of our figures of the rabbit corporal smooth muscle relaxation experiments that supported the concept that NO was the mediator of penile erection, and in September of 1990, Nature published it, two months after the BBRC publication. 13 We had half of our wish realized at this time. Our studies on human corporal tissue began almost simultaneously as our rabbit tissue studies. In 1990, there was a report from Sjostrand et al.
14 , which was essentially the first publication on the role of NO in human corporal tissue and, for still unexplained reasons, they concluded that NO was definitely not involved in the relaxation of human corporal tissue. It has been speculated that the penile tissue of Sjostrand's patients, transsexuals who were undergoing a sex change operation, may have been exposed to certain medications prior to the harvesting of their penile tissue, which may have led to their negative results regarding the role of NO. Alternatively, the authors used a relatively non-potent blocker of NO to inhibit their neurogenically induced relaxation of the corporal smooth muscle and this may have led to their false negative results.
In July of 1990, at my urging, one of our urology residents at UCLA, William J Aronson, MD, chose to spend his 1 year urologic research fellowship in Dr Ignarro's lab to continue these human studies and before the end of the year, our findings on the human tissue was submitted to the NEJM. The article was returned to us a few months later in early 1991 suggesting that we should re-do almost all of our experiments as a result of criticisms of the methodology used. We were dumbfounded that our methodology for working on smooth muscle contraction/relaxation was being challenged since Dr Ignarro's lab was now internationally recognized as one of the developers of the field. By April 1991, we had redone all our experiments and re-submitted the paper to the NEJM demonstrating that our results were exactly the same as our earlier submission and that the methodology that we used to study the function of the corporal smooth muscle was indeed the correct one and was the same that we had used in the BBRC and Nature publications.
As we awaited the decision of the editors at the NEJM, which took months and a timely phone call that October, by mid 1991 two other groups also reported on the role of NO in penile erection. Holmquist et al. Discovery of NO in the penis J Rajfer we had reported a year earlier in BBRC confirming the fact that NO appeared to be the mediator of penile erection in the rabbit, and in a subsequent two page publication very soon thereafter, they also reported that human corporal tissue from four patients responded very similar to what they observed in the rabbit and they proposed that NO was the chemical mediator involved in the human erectile response. 16 Around the same time, Kim et al. 17 , made similar claims with their publication in 1991 where they studied the corpora of both rabbits and men and came to the conclusion that the erectile response was similar in both rabbit and man, and in both species it appeared as if NO or an NO like factor was involved in this process.
That same year, we presented our human data for the first time at the Biennial Meeting of the Johns Hopkins Hospital in Baltimore, MD, on 9 June 1991. At that meeting, there was a junior resident in Urology at Hopkins by the name of Arthur Burnett, MD, who was preparing to start his laboratory year in 3 weeks and who on that day had his own proverbial light bulb turned on in his head. It was not until January of 1992 that the NEJM article was finally published and the unique observation of this study, which set it apart from the other previously published rabbit and human data, was that PDE inhibition enhanced the NO-cGMP response of the corporal tissue (Figure 4) . 3 It was only a few months later when Dr Burnett and his colleagues at Hopkins published their studies in the rat showing that not only was NO the mediator of penile erection in this animal model, but that NO was localized for the first time by antibody staining to the neurons in the penile tissue. 18 In early 1992, our group contacted Tom Lue in San Francisco to collaborate on a study that would use his dogs and our PDE inhibitor. This would prove or disprove whether these observations in the in vitro model was also operative in the in vivo setting. Indeed, Dr Aronson went to San Francisco to help perform the experiments and they were able to demonstrate that the PDE inhibitor did indeed enhance normal neurogenically induced erectile function ( Figure 5 ) in the canine model. For this work, Dr Trigo-Rocha, Dr Lue's fellow who spearheaded this study, won first prize for his presentation at the Western Section of the AUA in 1992. 19 
Common sense or no cents
Although both Lou Ignarro and I in 1992 tried to get our University to patent this work, the lawyers for UCLA determined that our 1990 publication in the BBRC prevented us from doing so since they believed the information was already in the 'public domain'. From a legal point of view, an investigator supposedly has 1 year from the date of a publication to be able to submit a patent. What everyone, including Dr Ignarro and I, missed was the fact that it was the response to the PDE inhibitor (M & B 22948 which later came to be known as zaprinast) that was not in the public domain until the 1992 NEJM publication. In fact, in a number of court decisions throughout the world since then, it is this January 9, 1992, date of the publication of the NEJM paper that is referenced as the time the clock began to tick for someone to patent drugs that impact the NO-cGMP pathway for the on-demand treatment of erectile dysfunction. What eluded us at UCLA has also prevented any drug company from patent protection for use of this pathway for the treatment of erectile dysfunction.
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Summary
The discovery of NO as the putative chemical mediator of erectile function was exhilarating as it Discovery of NO in the penis J Rajfer was scientifically rewarding for all of us who participated in this research at UCLA. We all shared in the joy when in 1998, the same year that Viagra was released into the marketplace, Dr Louis Ignarro was awarded a share of the Nobel Prize in Medicine in part for his contribution in elucidating the role of the NO-cGMP pathway in the erectile process. This discovery of NO in the penis was a classic collaborative effect and this review has attempted to recognize all those individuals who played major roles in this discovery. If nothing else, they have certainly earned the gratitude of those millions of patients who have benefited clinically from their discovery.
